Creo Medical Group (CREO)

Sector:

Health Care

Index:

FTSE AIM All-Share

36.00p
   
  • Change Today:
    -0.25p
  • 52 Week High: 48.10p
  • 52 Week Low: 23.25p
  • Currency: UK Pounds
  • Shares Issued: 361.48m
  • Volume: 164,806
  • Market Cap: £130.13m

Creo Medical accelerating EU launch of Speedboat UltraSlim

By Josh White

Date: Wednesday 25 Oct 2023

LONDON (ShareCast) - (Sharecast News) - Creo Medical Group announced the acceleration of its EU launch of the 'Speedboat UltraSlim' device by around 18 months on Wednesday.
The AIM-traded firm said the expedited timeline followed guidance from its notified body regarding the regulatory pathway.

It said Speedboat UltraSlim, a member of its Speedboat family of devices, was set to debut in early 2024 thanks to the newfound regulatory pathway.

The development would allow for an early adopter launch programme, which was initially slated for mid-2025.

Creo said the distinguishing feature of the UltraSlim is its compact size, in contrast to the Speedboat Inject.

That rendered the device compatible with all endoscopes boasting a 2.8mm working channel or larger, encompassing the majority of GI endoscopic procedures, extending the reach of its technology to a broader spectrum of clinicians and patients.

"This excellent news is testament both to the challenges the team have overcome to scale the technology down to a size which is as small as it ever needs to be, with the regulatory and clinical confidence needed to support this pathway," said chief executive officer Craig Gulliford.

"The regulatory landscape has been particularly challenging for all medtech companies in the last few years here in Europe, with changing transition deadlines and elongated and uncertain clearance pathways."

That, Gulliford said, had resulted in most companies seeking clearance now in the US ahead of the EU.

"We had adopted the same approach, planning to launch the device in the US ahead of the EU, having filed for our FDA clearance earlier this year.

"With this news, the accelerated timeframes will now see Creo, clinicians and patients reaping the benefits of widespread commercialisation of Speedboat UltraSlim in both Europe and the US in 2024."

At 1253 BST, shares in Creo Medical Group were up 0.75% at 33.75p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

CREO Market Data

Currency UK Pounds
Share Price 36.00p
Change Today -0.25p
% Change -0.69 %
52 Week High 48.10p
52 Week Low 23.25p
Volume 164,806
Shares Issued 361.48m
Market Cap £130.13m

CREO Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
23.43% below the market average23.43% below the market average23.43% below the market average23.43% below the market average23.43% below the market average
35.48% below the sector average35.48% below the sector average35.48% below the sector average35.48% below the sector average35.48% below the sector average
Price Trend
13.89% above the market average13.89% above the market average13.89% above the market average13.89% above the market average13.89% above the market average
35.14% above the sector average35.14% above the sector average35.14% above the sector average35.14% above the sector average35.14% above the sector average
Income Not Available
Growth
42.70% above the market average42.70% above the market average42.70% above the market average42.70% above the market average42.70% above the market average
66.67% above the sector average66.67% above the sector average66.67% above the sector average66.67% above the sector average66.67% above the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

CREO Dividends

No dividends found

Trades for 29-Apr-2024

Time Volume / Share Price
12:43 1,370 @ 36.47p
11:54 2,890 @ 36.00p
11:22 1,310 @ 36.00p
11:01 1,014 @ 36.00p
10:55 10,958 @ 36.38p

CREO Key Personnel

CEO Craig Jonathan Gulliford
CFO Richard John Rees

Top of Page